Citations

Clear

590 citation(s) found for "Ho, Ben".

Abstract 17597: Quantitative T Wave Analysis Can Identify Patients With Symptomatic Long QT Syndrome
Sugrue, Alan , Qiang, Bo , Friedman, Paul A. , Ackerman, Michael J. , Bos, J. Martijn , Křemen, Václav , Qiang, Bo, Noseworthy, Peter A.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 132 | Issue: suppl_3 | Pages: No page available

10.1161/circ.132.suppl_3.17597 Get It

Introduction: Long QT syndrome (LQTS) is a genetic disorder associated with abnormal ventricular repolarization and a predisposition for torsade de pointes and sudden cardiac death. Identification of markers to elucidate high risk patients is of major practical importance. Our aim was to use a novel, automated quantitative T wave analysis program to distinguish symptomatic from asymptomatic LQTS patients. Methods: We analyzed a genotyped cohort of 420 patients (22 ± 15.7years, 43% male) with either LQT1 (61%) or LQT2 (39%). ECG analysis was conducted using novel software that we created to automatically detect subtle changes in T wave morphology. Symptomatic patients were defined as those with a history of syncope or resuscitated cardiac arrest that was suspected of being LQTS triggered. Classification was performed using the top three T wave features in a linear discriminant classifier by 10x10 cross-validation. Results: Symptomatic LQT1 patients have a greater QTc duration in lead aVF (437 msec vs 416 msec, p <0.0001), a greater T wave center of gravity on the x axis (COGx) in lead V2 (0.304 vs 0.280, p <0.0001) and longer Tpeak-Tend/QT in lead II (0.208 vs 0.188, p < 0.0001) than asymptomatic patients with LQT1. Use of these 3 features enabled classification of symptomatic status in 72% of LQT1 cases, compared to 68% when QTc was used to classify alone. Symptomatic LQT2 patients had a longer QTc in Lead 1 (460 vs 418 msec, p < 0.0001), COGx in 4th segment of T wave was greater in lead V5 (0.399 vs 0.350, p<0.0001), and the Tpeak-Tend interval in V2 was longer (126 vs 99 msec, P =0.0004). Use of these 3 features enabled correct classification in 73% of LQT2 cases, compared to 67% when QTc was used alone. Conclusions: Application of an automated T wave analysis program was able to identify T wave features that distinguished the patients who presented as symptomatic LQTS, associated with syncope or resuscitated cardiac arrest. Use of these features could help assess arrhythmic risk and guide management strategies for patients with LQTS.
Nondestructive Measurement of Regenerated Esophageal Biaxial Mechanical Properties Utilizing Sonometry For Determination of Directional Esophageal Regeneration
Aho, Johnathon M. , Barron, Matthew, Qiang, Bo , Wigle, Dennis A. , Tschumperlin, Daniel M, Qiang, Bo M, Urban, Matthew W.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 33 | Issue: S1 | Pages: No page available

10.1096/fasebj.2019.33.1_supplement.lb171 Get It

Esophageal diseases often necessitate resection of tissue. Current reconstruction options using autologous conduits such as stomach, colon, and small bowel have significant morbidity. Given these limitations in current therapy, we have developed a large animal model to regenerate short segments of esophageal tissue after circumferential full thickness resection. This is performed by implantation of an electrospun polyurethane tissue engineered graft which results in esophageal regrowth. These implantations have been performed both with cell based seeding the polymer scaffold and without with comparable regenerative results. It is possible that esophageal regeneration in this model has unequal contributions from either the proximal or distal esophagus. To determine preferential directionality of regeneration we aim to utilize biomechanical markers to suggest that there are unequal proximal and distal contributions to regenerated tissue. Given limited availability of regenerated tissue, use of a non‐destructive method to perform this testing would have significant utility. Through using our previously validated non‐destructive sonometric ex vivo method we aim to determine differences in mechanical behavior of the regenerated tissue in comparison to proximal and distal esophageal tissues. Using this method we are able to determine longitudinal and circumferential moduli and derive strain energy functions and parameters. Within this work we demonstrate that there are differences in mechanical behavior and that the regenerated tissue behaves more comparably to proximal esophageal tissue suggesting preferential regrowth and unequal contribution to regenerated tissue. This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .
Corrigendum to “Clinical Outcomes of Critically Ill Patients Using Inhaled Nitric Oxide (iNO) during Intrahospital Transport”
Koyfman, Leonid, Simchon, Omri, Koyfman, Anna , Moshinsky, Shoshana, Gruenbaum, Benjamin F. , Gal, Ron, Friger, Michael , Arotsker, Natan, Klein, Moti, Brotfain, Evgeni , Gruenbaum, Benjamin Fredrick, Brotfain, Evgeni , Gruenbaum, Benjamin Fredrick , Zlotnik, Alexander Anatolievich

Mayo Clinic

Critical Care Research and Practice | June 21, 2021 | Volume: 2021 | Issue: No issue available | Pages: 1-1

10.1155/2021/9794018 | PMID 34249376 Get It

Structural Basis for Improved Proteolytic Stability and Target Affinity of Disulfide engineered Human Kunitz‐type Serine Protease Inhibitors
Cohen, Itay , Shahar, Anat , Sankaran, Banumathi , Hockla, Alexandra , Papo, Niv , Coban, Matt , Caulfield, Thomas R. , Radisky, Evette S.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 33 | Issue: S1 | Pages: No page available

10.1096/fasebj.2019.33.1_supplement.472.1 Get It

Serine protease inhibitors of the Kunitz‐bovine pancreatic trypsin inhibitor (BPTI) family, such as tissue factor pathway inhibitor‐1 Kunitz domain 1 ( KD1 TFPI1) and amyloid precursor protein inhibitor (APPI), are biological regulators of proteolysis and serve as important scaffolds for developing therapeutics. Mesotrypsin is a unique human protease with cancer‐promoting properties which rapidly cleaves and inactivates serine protease inhibitors; because of this, it is a challenging therapeutic target and an excellent model for developing therapeutic inhibitors with improved proteolytic resistance. We hypothesize that stabilization of the Kunitz inhibitor binding loop by disulfide bond anchoring to the scaffold can reduce proteolytic susceptibility and improve binding efficacy. Here we have engineered a new disulfide bond into both KD1 TFPI1 and an APPI variant previously engineered for mesotrypsin affinity. The new disulfide bond anchors the binding loop to the scaffold, resulting in reduced mesotrypsin proteolytic cleavage by 17‐fold and 3‐fold, respectively. To gain insight into the structural basis for improved proteolytic stability, we crystallized mutant KD1 TFPI1 and APPI with mesotrypsin and solved these novel structures. We then performed all‐atom molecular dynamics simulations using these mesotrypsin‐mutant inhibitor complexes compared to models lacking the engineered disulfide bond. Our simulation results support our hypothesis that the cause of decreased proteolysis rates is dampened conformational fluctuations in the binding loop and minimized motion at the enzyme‐inhibitor interface. We also performed simulations using unbound inhibitors to show that stabilization of the binding loop to states similar to the bound configuration correlates with stronger binding affinity. Our disulfide engineering approach is potentially a useful tool in biopharmaceutical development for mesotrypsin, other serine proteases, and possibly for other enzyme targets. Support or Funding Information NIH grant R01CA154387 to E.S.R., European Research Council grant 336041 to N.P., US‐Israel Binational Science Foundation grant BSF2015134 to E.S.R. and N.P. Xray diffraction data were measured at the Berkeley Center for Structural Biology at the Advanced Light Source and at the European Synchrotron Radiation Facility. This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .
Retinoic acid induces a metabolic switch in SH‐SY5Y cells from glycolysis to oxidative phosphorylation
Xun, Zhiyin, Lee, Do Yup , Lim, James , Canaria, Christie A., Barnebey, Adam, Yanonne, Steve, Bowen, Ben, McMurray, Cynthia T. , Northen, Trent R.

Mayo Clinic

The FASEB Journal | June 21, 2021 | Volume: 26 | Issue: S1 | Pages: No page available

10.1096/fasebj.26.1_supplement.967.1 Get It

Retinoic acid (RA) is used in differentiation therapy to treat a variety of cancers including neuroblastoma. The basis for its therapeutic efficacy is unknown, however, mitochondria (MT) have been implicated as key effectors in RA‐mediated differentiation process. Here we use the SH‐SY5Y human neuroblastoma cell line as a model to examine the contribution of MT to the physiological effects of RA treatment. We find that RA induces a dramatic increase in the energy metabolism of SH‐SY5Y cells, and shifts the dependence on energy production from glycolysis to oxidative phosphorylation. RA treatment does not increase the number of MT or cause measurable changes in the composition of the electron transport chain. Rather, RA treatment elevates the production of intracellular pyruvate as fuel for mitochondrial consumption, and significantly enhances the mitochondrial respiratory capacity. We propose a competition model for the therapeutic effects of RA. Specifically, the high metabolic rate in differentiated cells limits the availability of metabolic nutrients for use by the undifferentiated cells and suppresses their growth. Thus, RA treatment provides a selective advantage for the differentiated state.
Diagnosis and Treatment of Femoral Head Osteonecrosis: A Protocol for Development of Evidence-Based Clinical Practice Guidelines
Cui, Quanjun , Baek, Seung‐Hoon , Drescher, Wolf , Hernigou, Philippe , Jones, Lynne C. , Koo, Kyung‐Hoi , Lee, Mel, Mont, Michael A. , Reichert, Ines , Salem, Hytham S. , Stronach, Ben M., Sugano, Nobuhiko , Zhao, Dewei , Cheng, Edward Y. , Goodman, Stuart B. , Ando, Wataru , Bakker, Caitlin , Kim, Harry K.W. , Kim, Shin‐Yoon , Kim, Tae-Young , Ha, Yong‐Chan , Sakai, Takashi , Sierra, Rafael J. , Yamamoto, Takuaki , Yoon, Byung‐Ho

Mayo Clinic

Surgical Technology Online | June 14, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.52198/21.sti.38.os1437 | PMID 34043232 Get It

Introduction: There are many treatment options for patients who have osteonecrosis of the femoral head (ONFH) and management strategies vary widely both among and within individual countries. Although many researchers have attempted to elucidate the optimal strategies for managing this disease, the lack of large-scale randomized control trials and the lack of agreement on disease staging have curtailed the development of clear-cut guidelines. Materials and Methods: The Association Research Circulation Osseous (ARCO) group sought to address three questions for the management of patients who have ONFH: 1) What imaging studies are most sensitive and specific for the diagnostic evaluation of patients who have ONFH?; 2) What is the best treatment strategy for preventing disease progression in patients who have pre-collapse lesions?; and 3) What is the best treatment strategy for patients who have post-collapse disease? The Patient, Intervention, Comparison, and Outcome (PICO) format was used to formulate the search strategy for each research question. A systematic review will be performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. ARCO participants have been allocated to three groups, each representing one of the PICO questions. After qualitative and quantitative analysis of the data extracted from studies pertaining to each of the three research questions, a set of evidence-based clinical practice guidelines will be proposed for the management of patients who have ONFH. Discussion: It is not always clear which treatment method is optimal for the management of ONFH. Thus, many surgeons have developed and performed various procedures based on patient-specific factors. As there is no consensus on the optimal treatment for various stages of disease, it was clear that developing evidence-based clinical practice guidelines would provide more structure and uniformity to management of these patients. Therefore, the results of this systematic review will lead to the development guidelines that may improve patient-care strategies and result in better outcomes for patients who have ONFH.
A Systematic Review and Meta-Analysis of Cell-Based Interventions in Experimental Diabetic Kidney Disease
Hickson, LaTonya J. , Abedalqader, Tala, Ben-Bernard, Gift, Mondy, Jayla , Bian, Xiaohui , Conley, Sabena M., Zhu, Xiangyang , Kukla, Aleksandra , Lorenz, Elizabeth C. , Lerman, Lilach O. , Mondy, Jayla M, Kim, Seo Rin , Thorsteinsdottir, Bjorg , Lerman, Lilach O , Hickson, LaTonya J , Abedalqader, Tala , Herrmann, Sandra M. , Murad, M. Hassan

Mayo Clinic

Stem Cells Translational Medicine | June 9, 2021 | Volume: 10 | Issue: 9 | Pages: 1304-1319

10.1002/sctm.19-0419 | PMID 34106528 Get It

AbstractRegenerative, cell-based therapy is a promising treatment option for diabetic kidney disease (DKD), which has no cure. To prepare for clinical translation, this systematic review and meta-analysis summarized the effect of cell-based interventions in DKD animal models and treatment-related factors modifying outcomes. Electronic databases were searched for original investigations applying cell-based therapy in diabetic animals with kidney endpoints (January 1998-May 2019). Weighted or standardized mean differences were estimated for kidney outcomes and pooled using random-effects models. Subgroup analyses tested treatment-related factor effects for outcomes (creatinine, urea, urine protein, fibrosis, and inflammation). In 40 studies (992 diabetic rodents), therapy included mesenchymal stem/stromal cells (MSC; 61%), umbilical cord/amniotic fluid cells (UC/AF; 15%), non-MSC (15%), and cell-derived products (13%). Tissue sources included bone marrow (BM; 65%), UC/AF (15%), adipose (9%), and others (11%). Cell-based therapy significantly improved kidney function while reducing injury markers (proteinuria, histology, fibrosis, inflammation, apoptosis, epithelial-mesenchymal-transition, oxidative stress). Preconditioning, xenotransplantation, and disease-source approaches were effective. MSC and UC/AF cells had greater effect on kidney function while cell products improved fibrosis. BM and UC/AF tissue sources more effectively improved kidney function and proteinuria vs adipose or other tissues. Cell dose, frequency, and administration route also imparted different benefits. In conclusion, cell-based interventions in diabetic animals improved kidney function and reduced injury with treatment-related factors modifying these effects. These findings may aid in development of optimal repair strategies through selective use of cells/products, tissue sources, and dose administrations to allow for successful adaptation of this novel therapeutic in human DKD.